FDA Grants Priority Review to Johnson & Johnson's Amivantamab for Advanced Head and Neck Cancer — Johnson & Johnson

Event summary

FDA grants Priority Review to Johnson & Johnson's subcutaneous amivantamab for recurrent/metastatic head and neck squamous cell carcinoma (HNSCC).
OrigAMI-4 study shows 42% overall response rate, with one-third achieving complete response.
Amivantamab targets both EGFR and MET receptors, which are overexpressed in 80-90% of HNSCC tumors.
Priority Review shortens FDA review timeline to approximately six months.

The big picture

Johnson & Johnson's amivantamab represents a strategic pivot into head and neck cancer, an area with limited treatment options and poor survival rates. The Priority Review underscores the FDA's recognition of its potential to address significant unmet needs in oncology. This move aligns with broader industry trends toward targeted therapies that combine tumor growth inhibition with immune system engagement.

What we're watching

Approval Timeline: Whether the FDA will approve amivantamab within the six-month Priority Review period, potentially expanding its use in HNSCC.
Market Expansion: How Johnson & Johnson leverages this approval to position amivantamab as a first-in-class treatment across multiple tumor types beyond lung cancer.
Competitive Dynamics: The pace at which competitors develop similar EGFR- and MET-targeted therapies for HNSCC, given the high unmet need in this indication.